(Q38059916)

28 August 2017

Immune responses and protection in children in developing countries induced by oral vaccines (English)

1 reference

28 August 2017

1

Firdausi Qadri

1 reference

28 August 2017

4

Ann-Mari Svennerholm

1 reference

28 August 2017

3

David A Sack

1 reference

28 August 2017

Taufiqur Rahman Bhuiyan

series ordinal

2

1 reference

PubMed ID

23153448

28 August 2017

language of work or name

English

0 references

publication date

12 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

31

1 reference

28 August 2017

3

1 reference

28 August 2017

452-460

1 reference

Immunology of Gut Mucosal Vaccines

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Where and why are 10 million children dying every year?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Maternal and child undernutrition: global and regional exposures and health consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

What works? Interventions for maternal and child undernutrition and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Rotavirus and severe childhood diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Chronic helminth infections induce immunomodulation: consequences and mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Typhoid fever in children aged less than 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Mucosal immunity to poliovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

New strategies for the elimination of polio from India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Does B.C.G. vaccination prevent or postpone the occurrence of tuberculous meningitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Studies of diarrheal disease in Central America. X. Associated chickenpox, diarrhea and kwashiorkor in a highland Guatemalan village

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Studies of diarrheal disease in Central America. 8. Measles, diarrhea, and nutritional deficiency in rural Guatemala

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Relationship between household wealth inequality and chronic childhood under-nutrition in Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

VITAMIN A AS AN ANTI-INFECTIVE AGENT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Vitamin A supplementation enhances infants' immune responses to hepatitis B vaccine but does not affect responses to Haemophilus influenzae type b vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Intestinal CD103+ dendritic cells: master regulators of tolerance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Epidemic influenza and vitamin D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Contribution of selected vitamins and trace elements to immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effects of early childhood supplementation with and without stimulation on later development in stunted Jamaican children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Systematic review of the efficacy and effectiveness of complementary feeding interventions in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Studies of breast-feeding and infections. How good is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Observations on the adequacy of breast-feeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Breastfeeding and the risk of life-threatening enterotoxigenic Escherichia coli diarrhea in Bangladeshi infants and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Breast feeding and the risk of severe cholera in rural Bangladeshi children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Prospective study of diarrhoeal disease in a cohort of rural Mexican children: incidence and isolated pathogens during the first two years of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Risk of diarrhea during the first year of life associated with initial and subsequent colonization by specific enteropathogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Protection against cholera in breast-fed children by antibodies in breast milk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Enteric infections, diarrhea, and their impact on function and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

APOE4 protects the cognitive development in children with heavy diarrhea burdens in Northeast Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effect of cryptosporidial and giardial diarrhoea on social maturity, intelligence and physical growth in children in a semi-urban slum in south India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Giardiasis as a predictor of childhood malnutrition in Orang Asli children in Malaysia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Giardia lamblia carriage in Israeli Bedouin infants: risk factors and consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Giardiasis and other intestinal parasitic infections in relation to anthropometric indicators of malnutrition: a large, population-based survey of schoolchildren in Tehran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effect of periodic antiascaris and antigiardia treatment on nutritional status of preschool children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Impact of Giardia intestinalis on vitamin a status in schoolchildren from northwest Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Child undernutrition, tropical enteropathy, toilets, and handwashing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Tropical enteropathy: a T-cell-mediated crypt hyperplastic enteropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Effect of diarrhea on the humoral response to oral polio vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Microbial ecology: human gut microbes associated with obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Metagenome of the gut of a malnourished child

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Human nutrition, the gut microbiome and the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Diarrhea in developed and developing countries: magnitude, special settings, and etiologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

Intelligence and lifelong learning. What's new and how can we use it?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.11.012

1 reference

28 August 2017

1 reference

PubMed ID

23153448